{"url_path":"/sec/gyre/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028716-index.html","accession_number":"0001140361-26-028716","cik":"0001124105","ticker":"GYRE","issuer_name":"GYRE THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1124105/0001140361-26-028716-index.html","primary_entity_key":"0001124105","primary_entity_name":"GYRE THERAPEUTICS, INC."},"word_count":97,"has_tables":true,"body_markdown":"Item 9.01\n\nFinancial Statements and Exhibits.\n\n \n\n(d) Exhibits. The following exhibits are being furnished herewith:\n\n \n\n   \n\nExhibit Number\n\n \n\nExhibit Title or Description\n\n \n \n \n\n[99.1](ef20078088_ex99-1.htm)\n\n \n\nPress Release, dated July 16, 2026\n\n \n \n \n\n104\n\n \n\nCover Page Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n2\n\n \n\nSIGNATURE\n\n \n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\n \n\n \n\n \n\nGYRE THERAPEUTICS, INC.\n\n \n\n \n\nDate: July 16, 2026\n\nBy:\n\n/s/ Thomas Eastling\n\n \n\nName:\n\nThomas Eastling\n\n \n\nTitle:\n\nChief Financial Officer\n\n \n\n \n\n 3\n\nNASDAQ\n0001124105\nfalse\n\n0001124105\n\n2026-07-10\n2026-07-10"}